The founding team behind cancer company, Molecular Templates, has come together with its original seed investor to tackle the growing problem of prohibitively costly biologic medicines in the treatment of major inflammatory diseases such as rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn's disease. D5Pharma takes the stance that such drugs are unnecessarily large, complicated and immunogenic, and are beyond the reach of many patients.
The potential for addressing the enormous challenges posed by cancer and inflammatory diseases using a reimagined aptamer-based technology is apparent.
Aptamers have long been touted as valid alternatives to expensive monoclonal antibodies for the treatment of many incapacitating and fatal diseases, but have largely met with clinical failure. Gariépy and Revers believe a new approach that focuses on rapidly identifying functionally relevant molecules will unlock the as yet untapped potential of the DNA aptamer drug class. D5Pharma is the result of this ambitious vision.
To read more about Molecular Templates, click here.